全文获取类型
收费全文 | 17278篇 |
免费 | 2260篇 |
国内免费 | 302篇 |
专业分类
耳鼻咽喉 | 271篇 |
儿科学 | 264篇 |
妇产科学 | 222篇 |
基础医学 | 624篇 |
口腔科学 | 243篇 |
临床医学 | 832篇 |
内科学 | 819篇 |
皮肤病学 | 120篇 |
神经病学 | 174篇 |
特种医学 | 855篇 |
外国民族医学 | 44篇 |
外科学 | 1787篇 |
综合类 | 2066篇 |
预防医学 | 648篇 |
眼科学 | 138篇 |
药学 | 626篇 |
11篇 | |
中国医学 | 228篇 |
肿瘤学 | 9868篇 |
出版年
2024年 | 28篇 |
2023年 | 267篇 |
2022年 | 441篇 |
2021年 | 797篇 |
2020年 | 751篇 |
2019年 | 718篇 |
2018年 | 663篇 |
2017年 | 726篇 |
2016年 | 809篇 |
2015年 | 768篇 |
2014年 | 1249篇 |
2013年 | 1229篇 |
2012年 | 1124篇 |
2011年 | 1179篇 |
2010年 | 1065篇 |
2009年 | 976篇 |
2008年 | 826篇 |
2007年 | 982篇 |
2006年 | 871篇 |
2005年 | 714篇 |
2004年 | 584篇 |
2003年 | 509篇 |
2002年 | 409篇 |
2001年 | 368篇 |
2000年 | 291篇 |
1999年 | 255篇 |
1998年 | 216篇 |
1997年 | 175篇 |
1996年 | 133篇 |
1995年 | 97篇 |
1994年 | 75篇 |
1993年 | 51篇 |
1992年 | 63篇 |
1991年 | 45篇 |
1990年 | 34篇 |
1989年 | 31篇 |
1988年 | 47篇 |
1987年 | 31篇 |
1986年 | 21篇 |
1985年 | 50篇 |
1984年 | 32篇 |
1983年 | 28篇 |
1982年 | 28篇 |
1981年 | 19篇 |
1980年 | 19篇 |
1979年 | 12篇 |
1978年 | 9篇 |
1977年 | 14篇 |
1976年 | 5篇 |
1975年 | 3篇 |
排序方式: 共有10000条查询结果,搜索用时 28 毫秒
21.
《Journal of endodontics》2020,46(10):1371-1386.e8
IntroductionThis study aimed to summarize data on apical periodontitis (AP) and nonsurgical root canal treatment (NSRCT) prevalence and risk factors related to age, gender, and quality of restorative and endodontic treatment in the general population from cross-sectional studies published between 2012 and 2020.MethodsAn electronic search was performed in the following databases: Web of Science, Scopus, and PubMed. The conducted literature search covered studies published between 2012 and 2020, without restrictions on language. The STROBE and NOS tools were used for quality assessment of the included studies.ResultsSixteen articles were included in the review. In total, 200,041 teeth were examined. On average, 6.3% of teeth had AP, and 7.4% had NSRCT. Forty-one percent of RCT teeth had AP, and 3.5% of untreated teeth had AP. Female patients were less prone to AP in endodontically treated teeth only, compared with male patients (P < .001). Variable stratification of age subgroups among included studies prevented us from conducting a meta-analysis. An increase in AP frequency was found in teeth with inadequate restorative and endodontic treatment (P < .001 and P < .001, respectively). Because of high heterogeneity, these results should be taken with caution.ConclusionsThere is an increased AP prevalence in the adult general population compared with data from 2012 (6.3% versus 5.4%) in both endodontically treated (41.3% versus 35.9%) and untreated teeth (3.5% versus 2.1%). In addition, AP developed less frequently in female patients with endodontically treated teeth and in teeth with inadequate compared with adequate restorative and endodontic treatment. 相似文献
22.
《Obstetrics, Gynaecology and Reproductive Medicine》2020,30(10):303-308
Cancer is rarely diagnosed during pregnancy, but the incidence of cases is increasing. Diagnosis may be delayed due to an assumption that symptoms are pregnancy-related, or a reluctance to perform investigations. Multidisciplinary discussion is vital, with decision-making involving the obstetrician, patient and family. Many cancers can be treated during pregnancy. Surgery is considered safe and chemotherapy after the first trimester does not increase fetal risks. Timing and mode of delivery will depend on the treatment plans as well as obstetric considerations. The rate of preterm birth is increased, but overall neonatal and paediatric outcomes do not seem to be affected. 相似文献
23.
24.
目的 探讨接受新辅助放化疗的局部晚期食管鳞癌患者新辅助放疗剂量与病理完全缓解(pCR)的关系。方法 收集2017-2019年间在四川大学华西医院肿瘤中心经病理确诊为食管鳞癌并接受新辅助放化疗和手术的 116例局部晚期患者临床资料。116例患者中 40~45Gy组 80例,≥45Gy组 36例,分析两组术后pCR率。结果 全组患者的pCR率为38.8%(45/116),40~45Gy组与≥45Gy组的pCR率分别为44%(35/80)和28%(10/36)(P=0.105)。结论 术前新辅助采用较高的放疗剂量不增加局部晚期食管鳞癌的pCR率,有必要进行前瞻性的临床研究确定合适的新辅助放疗剂量。 相似文献
25.
While once considered as incurable systemic disease, treatment options for liver metastases have increased over the last 30 years and safety has improved dramatically, such that for a selected group of patients the hope of cure can now be offered with radical treatment, and low morbidity interventions can be offered which prolong survival, even in patients with more widely disseminated disease. Advances have been made in selection and surgical technique for liver resection and several adjuncts to resection now exist in the form of portal vein embolization, thermal ablation and targeted drug or radiotherapy delivery options. A natural consequence of these developments has been the delivery of services within fewer specialist units, with the result that later complications of therapy may present to local hospitals, rather than directly to the specialist centres. This article will describe the current common liver-directed therapies and outline the presentation and management of their complications. 相似文献
26.
27.
Rohini KhuranaSatyajeet RathHarikesh Bahadur SinghMadhup RastogiSambit Swarup NandaAbhishek ChauhanMohammad KaifNuzhat Hussain 《Asian Pacific journal of cancer prevention》2020,21(3):755-760
Background: The standard of care in high grade glioma (HGG) is maximal safe surgical resection followed by adjuvant radiotherapy (RT) with/without chemotherapy. For anaplastic gliomas, studies have shown use of procarbazine, lomustine, vincristine (PCV) improves overall survival (OS) and progression free survival (PFS). Currently, there is substantial evidence that molecular markers strongly predict prognosis and response to treatment. Methods: Between January 2016 to January 2018, 42 patients were accrued and followed up till April 2019. The primary end points were to correlate molecular markers with response to therapy in terms of OS and PFS in HGG. The secondary end point was to evaluate frequency of 1p/19q codeletion, IDH 1 mutation, ATRX deletion and p53 in HGG patients. Results: The median age was 46 years (range 18-67) with M:F ratio 30:12. The frequency of IDH1 mutation,1p/19q codeletion, p53 mutation and ATRX mutation were 42.8%, 16.6%, 42.8% and 14.2% respectively. All the seven patients with 1p/19q codeletion had IDH1 mutation. Median follow up was 22 months. The 20-months PFS for different mutations were as follows; IDH1-mutated vs wild type: 53.6% vs 29.8%; p-0.035, 1p/19q codeleted vs non-codeleted: 85.7% vs 62.3%; p-0.011, p53 wild type vs mutated 32.1% vs 35.6%; p-0.035 and ATRX lost vs retained: 55.6% vs 53.3%; p- 0.369. The 20-months OS for IDH1 mutated vs wild type: 82.4% vs 30.6%; p-0.014, 1p/19q codeleted vs non-codeleted: 85.7% vs 65.8%; p-0.104, p53 wild-type vs mutated 45.5% vs 73.9%; p-0.036 and ATRX lost vs retained: 100% vs 60.3%; p-0.087. Conclusion: Codeletion of 1p/19q with IDH1 mutation in HGG is associated with a significantly favourable PFS. However, larger studies with longer follow up are required to evaluate OS and PFS in all the molecular subgroups. 相似文献
28.
《Clinical lung cancer》2020,21(5):443-449.e4
BackgroundTraditionally, elective nodal irradiation (ENI) has been used in clinical trials that have established thoracic radiotherapy as instrumental in improving survival for patients with limited-stage small-cell lung cancer (LS-SCLC). However, several reports have suggested that the omission of ENI might be appropriate. Current US practice patterns are unknown regarding ENI for patients with LS-SCLC.Materials and MethodsWe surveyed US radiation oncologists via an institutional review board-approved questionnaire. The questions covered demographics, treatment recommendations, and self-assessed knowledge of key clinical trials. χ2 and Cochran-Armitage tests were used to evaluate for statistically significant correlations between responses.ResultsWe received 309 responses. Of the respondents, 21% recommended ENI for N0 LS-SCLC, 29% for N1, and 30% for N2; 64% did not recommend ENI for any of these clinical scenarios. The respondents who recommended ENI were more likely to have been practicing for > 10 years (P < .001), more likely to be in private practice (P = .04), and less likely to be familiar with the ongoing Cancer and Leukemia Group B 30610 trial (P = .04). Almost all respondents (93%) prescribed the same radiation dose to the primary disease and involved lymph nodes. When delivering ENI, 36% prescribed the same dose to the involved and elective nodes, and 64% prescribed a lower dose to the elective nodes.ConclusionNearly two thirds of respondents did not recommend ENI, which represents a shift in practice. A recent large clinical trial that omitted ENI reported greater overall survival than previously reported and lower-than-expected radiation toxicities, lending further evidence that omitting ENI should be considered a standard treatment strategy. 相似文献
29.
同步放化疗是不可手术局部晚期食管癌的标准治疗模式,国际推荐根治性放疗剂量为50.0~50.4Gy,但中国食管癌与西方国家在病理类型、生物学行为等方面大有不同,行根治性放疗剂量仍倾向于60Gy。增加放疗剂量能否带来生存获益成为临床亟待解决的问题。有研究认为高剂量放疗可提高局控率、改善生存,但也有研究认为提高剂量未能带来生存获益,且可增加不良反应事件发生率。因此,本文就食管癌根治性放疗剂量对预后的影响进行探讨,并通过放化疗后疗效评估对放疗剂量做出适当调整,以期达个体化放疗。 相似文献
30.
Stereotactic body radiotherapy (SBRT) has become an important radiotherapy technology. In recent years, with the continuous improvement of the mechanical properties of the linear accelerator (LINAC), LINAC-based SBRT is gradually emerging. In this article, the history, technological progress, radiation physics, clinical application of LINAC-based SBRT were elaborated, aiming to promote the development of LINAC-based SBRT. 相似文献